FOR LABORATORY RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION
◀ INDEXREPORT

REGULATORY STATUS MATRIX · 17 PEPTIDES × 10 COUNTRIES

For Laboratory Research Use Only. Not for human consumption. This is informational only and does not constitute legal, medical, or regulatory advice. Status changes. Verify against the linked source before relying on any cell in this table.

Cross-jurisdictional regulatory status as of 2026-05-19. Free dataset under CC BY 4.0. Each cell links to the primary government or international authority source that documents the status (where one was located). Cells marked Unknown were not assignable from a primary public source at the date of regeneration.

HOW TO READ THIS TABLE

Each row is one compound. Each column is one of the 10 jurisdictions in scope: the United States, European Union (treated as a single regulatory bloc), United Kingdom, Australia, Canada, Japan, South Korea, Brazil, India, and the United Arab Emirates. Cell values use the following five-category scheme.

  • RUO: research use only. The compound is sold as a chemical reference material for in-vitro laboratory work. It is not approved for human use and is not legally compounded or prescribed.
  • OTC: over-the-counter. The compound is sold without prescription as a cosmetic ingredient or dietary supplement, subject to the jurisdiction's labeling and quality rules for that category.
  • Rx: prescription required. The compound is approved as a finished pharmaceutical product and dispensed under the jurisdiction's prescription-medicine framework.
  • Scheduled: scheduled, controlled, or otherwise restricted under the jurisdiction's controlled-substances or poisons regime.
  • Banned: banned, restricted, or prohibited from sale. This category also captures substances on the WADA Prohibited List where the WADA listing is the most enforceable real-world constraint on the compound's circulation in the jurisdiction.

LEGEND

RUO · Research Use OnlyOTC · Over-the-counter / cosmetic / supplementRx · Prescription requiredScheduled · Scheduled / controlledBanned · Banned, restricted, WADA-prohibitedUnknown · No primary source located

MATRIX

COMPOUNDUSEUUKAUCAJPKRBRINAE
RetatrutideRUORUORUORUORUOUnknownUnknownUnknownUnknownUnknown
TirzepatideRxRxRxRxRxRxRxRxRxUnknown
BPC-157RUORUORUOBannedRUOUnknownUnknownUnknownUnknownUnknown
GHK-CuOTCOTCOTCOTCOTCOTCOTCOTCUnknownUnknown
TB-500RUORUORUOBannedRUOUnknownUnknownUnknownUnknownUnknown
NAD+OTCOTCOTCOTCOTCOTCOTCOTCOTCUnknown
MOTS-cRUORUORUORUORUOUnknownUnknownUnknownUnknownUnknown
TesamorelinRxRxRxRxRxUnknownUnknownUnknownUnknownUnknown
SelankRUOUnknownUnknownBannedUnknownUnknownUnknownUnknownUnknownUnknown
SemaxRUOUnknownUnknownBannedUnknownUnknownUnknownUnknownUnknownUnknown
CJC-1295RUORUORUOBannedRUOUnknownUnknownUnknownUnknownUnknown
SS-31RUORUORUORUORUOUnknownUnknownUnknownUnknownUnknown
5-Amino-1MQRUORUORUORUORUOUnknownUnknownUnknownUnknownUnknown
AdamaxRUOUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknown
IGF-1 LR3RUOBannedBannedBannedBannedBannedBannedBannedBannedBanned
KLOW BlendRUORUORUORUORUOUnknownUnknownUnknownUnknownUnknown
Wolverine BlendRUORUORUOBannedRUOUnknownUnknownUnknownUnknownUnknown

WHAT THE MATRIX SHOWS

Three structural patterns repeat across the table. First, the two incretin compounds that have completed full regulatory review (the GLP-1 / GIP dual agonist, tesamorelin) sit in the Rx column almost uniformly across the developed jurisdictions in scope. They are marketed under conventional pharmacy channels and behave as ordinary prescription medicines. the triple-receptor incretin agonist, still under Phase 3 evaluation as of this report's regeneration date, is uniformly RUO and will move into the Rx column country-by-country as its trial program reads out and dossiers are filed.

Second, Australia's Therapeutic Goods Administration is the most aggressive small-peptide regulator in this sample. The TGA's Schedule 10 capture of BPC-157, TB-500, and several other research peptides (with Selank and Semax also restricted) produces the most Banned cells in any single jurisdiction column. Australia's position is an outlier rather than a precedent: most other developed jurisdictions treat these compounds as chemical reference material rather than scheduling them directly. Even so, the Australian listing has practical implications because international shipping carriers mirror national-list controls in their dangerous-goods screens.

Third, IGF-1 LR3 sits in the Banned column across almost every jurisdiction because the World Anti-Doping Agency Prohibited List captures it as a growth-factor analog under section S2. Where pharmacy law does not directly schedule the molecule, the WADA listing still functions as the binding constraint for any human-use channel that intersects sport, fitness, or licensed-athlete oversight.

Cells marked Unknown reflect gaps in primary-source coverage rather than a positive claim of unscheduled status. Several jurisdictions (notably Japan, South Korea, Brazil, India, and the UAE) publish authoritative drug-approval and controlled-substances registers but do not consistently index the smaller research peptides on this list in English-language form. We mark these cells Unknown rather than guessing.

METHODOLOGY

Each cell was assigned by consulting the national or international regulatory authority website linked from that cell (or, where no specific page was located, from the authority's home page listed in the source-authority table below). The five-category scheme is a coarse classification chosen for cross-jurisdiction comparability; individual cells frequently carry more nuance than the pill captures (for example, an Rx classification may apply only to a specific indication or formulation; an OTC classification may apply only to a specific concentration range). When in doubt the more restrictive category was preferred.

Retrieval date: 2026-05-19.
Update cadence: Quarterly. Next review 2026-08-19.

WADA cross-listing: the World Anti-Doping Agency Prohibited List applies independently of national pharmacy law. Where a compound is captured under WADA but not directly scheduled by the national authority, we record the cell as Banned with the WADA list as the source. The WADA list is available here and is reviewed annually.

Australia / TGA Schedule 10: Australia's Schedule 10 captures substances “of such danger to health as to warrant prohibition of sale, supply and use”. Schedule 10 entries cited in this matrix are read against the current Poisons Standard (SUSMP), linked from the cells where it applies.

SOURCE AUTHORITIES

DISCLAIMERS

Regulatory status changes. The matrix is a starting point for further verification, not a substitute for direct consultation of the relevant authority and legal counsel in the buyer's jurisdiction. Where this report shows RUO, that reflects research-grade chemical-reference sale and does not imply human-use authorization in any country. Where it shows Rx, the underlying approval is for a specific finished pharmaceutical product under a specific label; research-grade material of the same molecule is a separate category and not interchangeable with the approved product.

CITE THIS REPORT

Cite this report: GigaCompounds LLC. Regulatory Status Matrix · 17 Peptides × 10 Countries. Retrieved 2026-05-19 from gigaresearch.vercel.app/reports/regulatory-status-matrix

RELATED

© 2026 GigaCompounds LLC · For Laboratory Research Use Only